BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
1.-The manuscript shows that the main instrument of the study is a self-reported questionnaire 115 entailing questions on participants' socio-demographic characteristics, their involvement in the CPO and the CPO's level of representation, "among others." Moreover, the questionnaire encompassed the Patient Participation and Health Democracy Index (HDI), "an original scale measuring the degree of CPOs participation and its impact on shaping health policy." But the paper does not include the questionnaire as an annex, nor does it provide a reference to access it, and the description in the text does not give enough information about the complexity or the appropriateness to easily respond to it. Any suggestion to solve this issue?
2.-Following the topic of the questionnaire, the text states that it is a validated instrument ("an innovative and validated tool was employed in order to assess the level of cancer patient' organizations participation in health policy decision making"), but this is not explained in the Methods section. It is described that "… Both sub-scales displayed good internal consistency (Cronbach 144 a = 0,879 and Cronbach a = 0,874 respectively…, but further details about the validation efforts should be provided.
3.-The participants are portrayed as "1.266 members of Cancer Patient Organizations from the 28 EU countries." The authors recognize the potential limitation arising from the fact that this was a convenient sample. But beyond that limitation… the manuscript does not specify how many respondents were recruited per country (across the 28 Member States), nor the basic characteristics that allow to know the nature of the sample (age, sex, socioeconomic level, education ...). This should be clarified.
4.-The findings were simplified by classifying four groups of countries according to their score: a) high degree of participationhigh impact, b) high degree -low impact, c) low degree -high impact, d) low degree -low impact. But the scores (and cut points) were not shown, and no 'Sensitivity Analysis' seems to be carried out.
5.-The main body of the manuscript concludes with the specific case study of Italy (as an example of Low Degree -Low Impact country). This seems an abrupt way of ending, without formulating a discussion that integrates the visitation of the four types of Member States, and different from the conclusion which is in fact formulated in the Abstract ("Cancer patient' participation in health policy decision making processes varies significantly among EU-28 countries. Although progress has been made in upgrading the patients role in terms of legislation, however more need to be done in order to address inequalities in health policy decision 49 making between EU-countries and ensure that patient' voice is heard.") A better conclusion of the discussion section is recommended.
REVIEWER
Arja R Aro Unit for Health Promotion Research, Faculty of Health Sciences, University of Southern Denmark. Denmark REVIEW RETURNED 10-Oct-2017
GENERAL COMMENTS
This manuscript deals with an interesting topic of patient organization involvement in policy making in 28 EU countries. However, the manuscript unfortunately is very superficial in its way of reporting. It writes interchangeably about patient involvement and patient organization involvement in policy decisions. It fails to describe the policies dealt with, the context of each country setting where participation and impact have been measured. Though the instruments used seem to be relevant, the issues measured are not specific enough. The sample selection has been described in the manuscript, though the multiple ways of selecting participants also creates (unknown) heterogeneity and bring a lot of 'noise' to the results. The used cluster analysis is not described in the text. There are a number of assumptions that are not tested but underpin the approach to the reported research. Lines 70-72 suggest that increased spending is important for sustainability of healthcare systems. This is followed (lines 72-75) by the assertion that consequentially there is greater involvement of patients. This appears a non-sequitur; I do not understand how the first sentence relates to the second.
The example from Italy (lines238-246) does not make sense. What is the treatment that is being discussed? The grammar is also problematic
Conceptual issues
The title suggests that the research relates to the involvement of CPOS rather than individual members of CPOs in shaping health policy. But much of the discussion relates to policies for involving individual patients rather than CPOs. Similarly, it is unclear if respondents were answering on the basis of their personal experience of being involved vs the opportunities for patients to be involved vs the opportunities for CPOs to be involved. The lack of discussion of the distinction between collective organisational involvement and individual involvement undermines the approach to analysis and the interpretation of findings.
It is unclear what is meant by 'policy'. The examples that are presented from the UK relate first to involvement in research and latterly the involvement of patients in defining appropriate treatments available through the NHS. Neither of these cases shapes legislation (policy) although the second example might be seen to shape guidelines for practice. This is apparent in the references that are cited. The sentences lines 93-95; 95-97 suggests that processes exist to 'empower patients to take part in such processes' (lines 96-97) referring to policy processes. However, the reference relates not to involvement in policy but rather involvement in research.
No account is taken of the importance of the underlying structure of the health system. In the example of Finland where healthcare is organised and delivered by municipalities and they are responsible for carrying out health needs assessment. It is also worth noting that in Finland Overall, while this research is potentially important and there is a significant need for cross-national studies the definitional confusion in the conceptualisation of this study undermine its potential to make any contribution to the literature except to increase confusion.
REVIEWER

Mio Fredriksson
Department of Public Health and Caring Sciences, Uppsala University, Sweden REVIEW RETURNED 01-Nov-2017
GENERAL COMMENTS
The paper deals with an interesting question. However, it is poorly framed and there are many uncertainties in the methods and the interpretation of the results. Therefore, I feel compelled to reject it. The greatest problems with the paper is that 'patients' and 'the public' are used interchangeably although these two represent different interests in relation to the health services (see e.g. Fredriksson and Tritter, 2017) . The background and problem statement is also built on individual patient participation, which is quite different from collective patient participation, which is measured here, i.e. patient advocacy. Thus, the framing of the research question is faulty. Furthermore, there is no discussion of what health policy decision-making is. What types of decisions are referred to, and at what decision-making levels? The link between differences in cancer treatments and participation is also weak. Generally I lack information on which organizations are part of this study and how many respondents there were from the 28 countries (~42 from each country; is that enough?). There is no discussion about such limitations. As the results are rather surprising in many ways, the article would have benefited greatly from a discussion about how this can be understood or interpreted. Otherwise, the results rather seem untrustworthy and I wonder if the surveys captured participation correctly. In addition, how were the limits between the clusters decided upon? They seem arbitrary. Based on picture 1 it seems more reasonable that the clusters would stretch from -2 to 0 and from 0 to 2. But then the clusters would be different from those presented in the article. There is no discussion about this in the manuscript and the clusters should have been described more clearly based on the actual options in the survey. As it is now, we do not know how much participation is classified as high or low etc. And is there any association with the quality of cancer services in these countries? I think the actual item or index scores should have been presented as well. And how do the clusters (and the country values) comply with individual-level patient rights as presented by, e.g. the Euro Health Consumer Index 2016. I also wonder how the survey was translated. In my opinion, it is likely that some questions translates differently in the 28 countries, as is a highly timeconsuming task to translate surveys between diverging contexts. Furthermore, the four examples presented is no help understanding the results. The material presented in this section seems random and refers to both public and patient involvement.
VERSION 1 -AUTHOR RESPONSE
We would like to thank the reviewers for their valuable comments and the points they have raised, as they have helped us with the unique opportunity to think deeper about our study findings and their implications. We have tried to address their comments and incorporate their recommendations: Reviewer 1 "But the paper does not include the questionnaire as an annex, nor does it provide a reference to access it, and the description in the text does not give enough information about the complexity or the appropriateness to easily respond to it. Any suggestion to solve this issue?" Reply: Amendments have been made in line with the reviewer's query under Instrument in Methods section. "The text states that it is a validated instrument ("an innovative and validated tool was employed in order to assess the level of cancer patient' organizations participation in health policy decision making"), but this is not explained in the Methods section. It is described that "… Both sub-scales displayed good internal consistency (Cronbach 144 a = 0,879 and Cronbach a = 0,874 respectively…, but further details about the validation efforts should be provided." Reply: Information about its validation process has been added. Instrument in Methods section "The manuscript does not specify how many respondents were recruited per country (across the 28 Member States), nor the basic characteristics that allow to know the nature of the sample (age, sex, socioeconomic level, education ...). This should be clarified." Reply: Tables 1 and 2 have been added in line with the reviewer's query. "The findings were simplified by classifying four groups of countries according to their score: a) high degree of participation -high impact, b) high degree -low impact, c) low degree -high impact, d) low degree -low impact. But the scores (and cut points) were not shown, and no 'Sensitivity Analysis' seems to be carried out." Reply: A new table containing the median scores of each country along with the information for the total median scores from all countries was added in the results section. For the consistency and validity of the hypothesized groups of countries in the total sample; the total sample was divided into a split-half random sample. K-means clustering was used then for the two subsamples to determine the presence of similar cluster subgroups from the previous analyses and the initial solution was further confirmed. Additionally, Degree of Participation and Impact of Participation scores were compared between the four groups defined by cluster analysis and all results were significant. All new information is provided in the statistical analysis and results section. "The main body of the manuscript concludes with the specific case study of Italy (as an example of Low Degree -Low Impact country). This seems an abrupt way of ending, without formulating a discussion that integrates the visitation of the four types of Member States, and different from the conclusion which is in fact formulated in the Abstract ("Cancer patient' participation in health policy decision making processes varies significantly among EU-28 countries. Although progress has been made in upgrading the patients role in terms of legislation, however more need to be done in order to address inequalities in health policy decision 49 making between EU-countries and ensure that patient' voice is heard.") A better conclusion of the discussion section is recommended." Reply: We agree with the reviewer. We have made substantial changes in the Discussion of the manuscript. Moreover, we have also incorporated a conclusion, in line with the recommendation. Reviewer 2 "It writes interchangeably about patient involvement and patient organization involvement in policy decisions". Reply: We agree with the reviewer that public involvement is different from patient involvement and that patient involvement is different from patient organization involvement. The Introduction has been largely re-written to focus solely on patient organization participation. We have retained some information on shared decision making in clinical practice (patient participation on the individual level); however, we have added two paragraphs on patient organization participation. We draw on existing evidence on patient organization participation in health decision making in a attempt to elucidate the context of the study. In a similar vein, substantial changes have been made in the Discussion (changes in red font, while irrelevant text has been deleted) "It fails to describe the policies dealt with, the context of each country setting where participation and impact have been measured" Reply: We see the reviewer's point; however, we could not have elaborated on the context of each county setting. We have made some important changes in the Discussion in an attempt to shed light on the issues raised. "Though the instruments used seem to be relevant, the issues measured are not specific enough" Reply: We understand the reviewer's point. We have tried to address this issue by reframing the Introduction (paragraphs have been added and previous ones have been deleted), so as to place the study in better context. In addition, we have tried to clarify the development and validation of the Health Democracy Index in order to clarify what we mean by patient organization participation in health policy decision making. Finally, as already noted, we have re-written the Discussion to a large extent. "The sample selection has been described in the manuscript, though the multiple ways of selecting participants also creates (unknown) heterogeneity and bring a lot of 'noise' to the results" Reply: We agree with the reviewer. It is a great limitation that the study sample is a convenience sample and this is acknowledged as a limitation in the text. On the other hand, the existence of multiple ways for selecting participants may increase the likelihood of including a more representative sample. "The used cluster analysis is not described in the text" Reply: A new paragraph concerning statistical analysis description was added in the text.
"Further, no framework or conceptual definition of patient (organization) involvement in policy decisions is given. It is difficult to know what kind of participation is meant, what kind of impact etc." Reply: As before, the introduction has been largely re-written to be more focused on patient organization participation in health policy decision making. Likewise, the discussion of the manuscript. "Since no qualitative case descriptions are either included, the text remains rather technical and superficial. Based on these results, no real suggestions for improving the situation can be made". Reply: We see the reviewer's point; however, it would have been difficult to include qualitative case descriptions, as findings emanate from 28 different countries. We have largely re-written the Discussion in an endeavour to add more depth in the manuscript. We hope that the reviewer will find the revised version less technical and superficial.
"There are also issues such as ethics permission received from each cancer organization' institutional review boards. However, the organizations involved are not listed and I even wonder if all organizations in all countries do have institutional review board. So evidence on this is needed" Reply: Participation was anonymous and thus we could not identify the origin of responses. As the questionnaire entailed a question about respondents' position in the organization (president or other board member), during the pilot phase of the instrument we were asked to exclude from the questionnaire patient organizations' identification number in order not to jeopardize participants' anonymity. It merits noting that apart from the Institutional Review Board of the participating patients organizations, the study was also approved by the Research and Ethics Committee of the University of Peloponnese, Corinth, Greece in accordance with the ethical standards delineated in the 1964 Declaration of Helsinki. Reviewer 3 "There is a need for close proofreading for frequent grammatical errors". Reply: Amendments have been made in line with the reviewer's suggestion "Lines 70-72 suggest that increased spending is important for sustainability of healthcare systems. This is followed (lines 72-75) by the assertion that consequentially there is greater involvement of patients. This appears a non-sequitur; I do not understand how the first sentence relates to the second." Reply: We have rephrased this part in the Introduction. "The example from Italy (lines238-246) does not make sense. What is the treatment that is being discussed? The grammar is also problematic."
Reply: We agree with the reviewer. We have deleted this example. We have largely re-written the Discussion, so as to add more depth in our report. Please note that both the Introduction and Discussion have been re-written and that changes are highlighted in red font. "The lack of discussion of the distinction between collective organisational involvement and individual involvement undermines the approach to analysis and the interpretation of findings." Reply: We agree with the reviewer. We have reformulated the introduction (one and a half paragraphs deleted and two paragraphs have been added) in such a way as to place the study in the context of patient organization participation. In this way, the distinction between degree and impact of participation is better drawn; while it is also clarified what is mean by health policy decision making. A similar line is followed in the Discussion as well. "It is unclear what is meant by 'policy'. The examples that are presented from the UK relate first to involvement in research and latterly the involvement of patients in defining appropriate treatments available through the NHS. Neither of these cases shapes legislation (policy) although the second example might be seen to shape guidelines for practice. This is apparent in the references that are cited. The sentences lines 93-95; 95-97 suggests that processes exist to 'empower patients to take part in such processes' (lines 96-97) referring to policy processes. However, the reference relates not to involvement in policy but rather involvement in research." Reply: As before, we have re-written the introduction and the discussion in order to clarify what we mean by patient organization participation in health policy decision making. "No account is taken of the importance of the underlying structure of the health system. In the example of Finland where healthcare is organised and delivered by municipalities and they are responsible for carrying out health needs assessment. It is also worth noting that in Finland the Cancer Patient Organisation is primarily funded through government taxation on slot machines making the relationship between the voluntary sector and the state far from independent." Reply: We agree with the reviewer and we find the point raised very interesting. Unfortunately, due to including data from 28 countries with marked diversity in the underlying structure of the health care system and its performance, we could not have elaborated on these issues. We have largely rewritten the Discussion and we are currently working on a more focused paper exploring whether these findings are explained by existing legislation or characteristics of the health care system (e.g. Centralized vs. Decentralised). "There is insufficient discussion of what 'involvement' and 'impact' mean. The use of a 9 item Likert scale may generate high Cronbach alpha but what are they measuring? " Reply: As before, the introduction and discussion sections of the manuscript have been largely rewritten. "More problematically there is no list of the number of CPOs or respondents by country." Reply: The number of respondents per country has been added in Methods (Table 1) . We could not have collected the number of CPOs per country, as we could not have identified to which cancer patient organization participants belonged. As the questionnaire entailed a question about respondents' position in the organization (president or other board member), during the pilot phase of the instrument we were asked to exclude from the questionnaire patient organizations' identification number in order not to jeopardize participants' anonymity. Reviewer 4 The greatest problems with the paper is that 'patients' and 'the public' are used interchangeably although these two represent different interests in relation to the health services (see e.g. Fredriksson and Tritter, 2017) . Reply: The introduction has been largely re-written and any reference on public involvement has been deleted. We agree with the reviewer public and patient involvement are not synonymous. Furthermore, the discussion has also been re-written along those lines. The background and problem statement is also built on individual patient participation, which is quite different from collective patient participation, which is measured here, i.e. patient advocacy. Thus, the framing of the research question is faulty.
Reply: The study addresses patient participation at the collective level, indeed. We have largely rewritten the introduction, to make it more focused on patient organization participation. Similarly, the Discussion has been re-written as well. Furthermore, there is no discussion of what health policy decision-making is. What types of decisions are referred to, and at what decision-making levels? Reply: We have largely re-written the introduction in order to make all these issues clearer. The Discussion has also been re-written along those lines The link between differences in cancer treatments and participation is also weak. Reply: We agree, the introduction and discussion have been re-written, so as to place our study in a more appropriate context. Generally I lack information on which organizations are part of this study and how many respondents there were from the 28 countries (~42 from each country; is that enough Reply: The mean number of responders per country was 45, providing a total sample of 1266 participants; large enough to produce adequate power for the analysis. The information was added in the methods section. Please see Table 1 for the exact number of respondents per country. As the results are rather surprising in many ways, the article would have benefited greatly from a discussion about how this can be understood or interpreted. Otherwise, the results rather seem untrustworthy and I wonder if the surveys captured participation correctly. Reply: The Discussion has been largely re-written in an endeavour to interpret the study findings. We hope the reviewer will find the revised version of the manuscript improved. In addition, how were the limits between the clusters decided upon? They seem arbitrary. Based on picture 1 it seems more reasonable that the clusters would stretch from -2 to 0 and from 0 to 2. But then the clusters would be different from those presented in the article. There is no discussion about this in the manuscript and the clusters should have been described more clearly based on the actual options in the survey. Reply: More information about the statistical method and results was added in the text. The values presented in the figure are the z scores that the analysis was based on, rather than the actual values. Thus the centered line is on zero. I think the actual item or index scores should have been presented as well. Reply: A new table that presents the indexes scores per country was added in the results section. And how do the clusters (and the country values) comply with individual-level patient rights as presented by, e.g. the Euro Health Consumer Index 2016. Reply: We agree with the reviewer. We had in mind the European Health Consumer Index but we would like to thank the reviewer for shifting our attention to this. We have incorporated it in the Discussion. I also wonder how the survey was translated. In my opinion, it is likely that some questions translates differently in the 28 countries, as is a highly time-consuming task to translate surveys between diverging contexts. Reply: We see the reviewer's point; however, the survey instrument was translated from English to all foreign languages by a company with vast experience on scientific European surveys. Furthermore, the four examples presented is no help understanding the results. Reply: We agree with the reviewer. Please note that important changes have been made in the Discussion. The material presented in this section seems random and refers to both public and patient involvement. Reply: We have largely re-written this part. Thank you.
VERSION 2 -REVIEW
REVIEWER
Arja R. Aro University of Southern Denmark, Denmark REVIEW RETURNED 18-Feb-2018 Besides that, and although the English language of the text is acceptable, I suggest that the authors get editing help from someone with full professional proficiency in English to fine tune the language. Second, how is the degree of participation-variable coded? Is it a scale? Does it generate a lower score to answer "it is not a legal requirement but it often happens" than " it is a legal requirement and it never happens"? In that case, I think it doesn't measure actual participation very well.
A minor point is that the authors use Sweden as an example when they say that the needs of cancer patients remain largey unmet and refer to longer waiting-times in Sweden than Albania. I think that is a strange point of comparison as Sweden's cancer care results are rather good.
Furthermore, the manuscript needs proof-reding.
VERSION 2 -AUTHOR RESPONSE
We would like to thank the reviewers for their time in reading the revised version of our manuscript and for providing us with their valuable support and feedback. Please find below our response to them:
Reviewer 1
We would like to thank the reviewer for his encouraging feedback.
Reviewer: Line 26 in the abstract currently reads: "It is evident that patients with the same type…". I suggest to state: "There is evidence showing that patients with the same type…" Response: Amendments have been made in line with the reviewer's suggestion.
Reviewer: Lines 73-76 in the introduction should be deleted (since the phrase is duplicated in lines 77-79. Choose one or another phrase, but not repeat the same idea).
Response: Lines 73-76 have been deleted.
Reviewer: A minor point is that the authors use Sweden as an example when they say that the needs of cancer patients remain largey unmet and refer to longer waiting-times in Sweden than Albania. I think that is a strange point of comparison as Sweden's cancer care results are rather good.
Response: Sweden has been substituted by Ireland.
Reviewer: Furthermore, the manuscript needs proof-reading.
Response: The manuscript has been proof-read by an English native speaker.
VERSION 3 -REVIEW
REVIEWER
Arja R Aro Unit for Health Promotion Research, University of Southern Denmark, Denmark REVIEW RETURNED 20-Apr-2018
GENERAL COMMENTS
The changes and edits of the manuscript are acceptable and they have improved the manuscript. There is one minor error though: in Table 1 only 27 countries are listed and in Table 3 there are 28 countries; it looks Table 1 has omitted Finland. This should be corrected.
REVIEWER
Mio Fredriksson
Department of Public Health and Caring Sciences, Uppsala University REVIEW RETURNED 23-Apr-2018
GENERAL COMMENTS
My comments have been adressed.
VERSION 3 -AUTHOR RESPONSE
We would like to thank the reviewers for their time in carefully reading the revised version of our manuscript and for providing us with their feedback. We have added Finland in Table 1 . Moreover, in line with the editorial requirements, we have corrected typos and errors in the manuscript.
